Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538930 | 0.78 | TSHR (0.48) | ALDH1A1TDP1GAAMAPT | |
| SCHEMBL7849448 | 0.78 | HDAC8 (0.42) | HDAC8HDAC4HDAC2KIF11ACHE | |
| SCHEMBL1987884 | 0.77 | GABRA1 (0.52) | ACHERXRARXRBALDH1A1HPGD | |
| SCHEMBL129151 | 0.75 | HDAC8 (0.56) | HDAC8HDAC4HDAC2KIF11ACHE | |
| SCHEMBL11624973 | 0.75 | TSHR (0.39) | KIF11ALDH1A1RAB9ACA2MEN1 | |
| Bromide SCHEMBL7971154 | 0.74 | HDAC8 (0.39) | HDAC8HDAC4HDAC2KIF11ACHE | |
| Water SCHEMBL29289408 | 0.73 | HDAC8 (0.54) | HDAC8HDAC4HDAC2KIF11ACHE | |
| SCHEMBL663624 | 0.72 | TSHR (0.48) | KIF11ACHEALDH1A1HPGDALOX15 | |
| SCHEMBL7203019 | 0.72 | KIF11 (0.52) | HDAC8HDAC4HDAC2KIF11ACHE | |
| SCHEMBL64291 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| CN-115335365-B | Aminocyclobutane as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11919870-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-05 | — | — | US | disclosed |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2021191390-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| US-9029544-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| EP-2536733-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2675811-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | US | disclosed |
| EP-2536733-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012110599-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | WO | disclosed |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| WO-2011101424-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919870-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | MGLL, DAGLB, FAAH | HDAC8 2527/4885HDAC4 3231/4885HDAC2 1013/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | HDAC8 1852/4885HDAC4 1258/4885HDAC2 506/4885 |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | HDAC8 1520/4885HDAC4 1391/4885HDAC2 1648/4885 |
| US-11897872-B2 | Azaspirocycles as monoacylglycerol lipase modulators | MGLL, LPAR1, LPL | HDAC8 1847/4885HDAC4 1404/4885HDAC2 506/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HDAC8 1399/4885HDAC4 1404/4885HDAC2 659/4885 |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | HDAC8 2527/4885HDAC4 3231/4885HDAC2 1013/4885 |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | HDAC8 2527/4885HDAC4 3231/4885HDAC2 1013/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HDAC8 1339/4885HDAC4 1354/4885HDAC2 620/4885 |
| US-20130053404-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | CETP, MTTP, CES1 | HDAC8 1520/4885HDAC4 1391/4885HDAC2 1648/4885 |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | HDAC8 1520/4885HDAC4 1391/4885HDAC2 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.